Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$9.19 USD
-0.20 (-2.13%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $9.21 +0.02 (0.22%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Adverum Biotechnologies, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 97 | 186 | 305 | 430 | 166 |
Receivables | 0 | 0 | 6 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 5 | 6 | 5 | 10 |
Total Current Assets | 103 | 191 | 317 | 434 | 176 |
Net Property & Equipment | 15 | 35 | 33 | 28 | 25 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 1 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 4 | 3 | 1 | 1 |
Total Assets | 173 | 308 | 440 | 483 | 223 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 1 | 3 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 17 | 18 | 14 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 25 | 32 | 21 | 21 | 19 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 1 | 1 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 90 | 127 | 124 | 48 | 48 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,004 | 986 | 965 | 937 | 561 |
Retained Earnings | -920 | -803 | -648 | -503 | -385 |
Other Equity | 0 | -2 | -1 | 0 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 83 | 182 | 316 | 434 | 175 |
Total Liabilities & Shareholder's Equity | 173 | 308 | 440 | 483 | 223 |
Total Common Equity | 83 | 182 | 316 | 434 | 175 |
Shares Outstanding | 10.10 | 9.90 | 9.80 | 9.70 | 6.40 |
Book Value Per Share | 8.26 | 18.34 | 32.26 | 44.78 | 27.34 |
Fiscal Year End for Adverum Biotechnologies, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 97 | 117 | 141 | 164 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 6 | 8 | 6 | 5 |
Total Current Assets | NA | 103 | 125 | 147 | 169 |
Net Property & Equipment | NA | 15 | 16 | 32 | 33 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 3 | 4 | 4 | 4 |
Total Assets | NA | 173 | 197 | 241 | 276 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 2 | 1 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 13 | 16 | 18 | 17 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 25 | 29 | 45 | 46 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 90 | 94 | 110 | 118 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,004 | 999 | 995 | 990 |
Retained Earnings | NA | -920 | -896 | -863 | -832 |
Other Equity | NA | 0 | -1 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 83 | 103 | 131 | 158 |
Total Liabilities & Shareholder's Equity | NA | 173 | 197 | 241 | 276 |
Total Common Equity | 0 | 83 | 103 | 131 | 158 |
Shares Outstanding | 20.70 | 10.10 | 10.10 | 10.00 | 10.00 |
Book Value Per Share | 0.00 | 8.26 | 10.17 | 13.12 | 15.78 |